# Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

> **NCT04163575** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kecellitics Biotech Company Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** :Anti-CD22-CAR

## Key facts

- **NCT ID:** NCT04163575
- **Lead sponsor:** Kecellitics Biotech Company Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04163575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04163575, "Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04163575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*